As you may have heard, the COVID-19 Public Health Emergency (PHE) and national emergency (NE) are coming to a close on May 11, 2023. The focus of this article addresses the potential impact to commercial/employer plan enrollment shifts as a result of the unwinding of Medicaid continuous coverage protection.
Employer concerns are increasing in response to the rising number of "seven-figure costs" associated with emerging gene therapies. What does the future hold for employer coverage of advanced therapies?
What are employers various roles in promoting and improving the quality of care? Jorge Font explores how life science organizations can engage and support employers to raise their understanding of the value of certain therapeutic approaches aligned with the employers’ quest to improve quality and care for consumers.
